PCA062 in pCAD-positive Tumors.

Exclusion Criteria

• •1. CNS metastatic involvement
• •2. Clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological conditions.
• •3. A history of serious allergic reactions, which in the opinion of the investigator pose an increased risk of serious infusion reactions.
• •4. Monocular vision or has media opacities or any other condition that precludes monitoring of the retina or the fundus, or has a history of ophthalmology exam with retina or cornea abnormalities
• •5. Previously treated with anti-pCAD biologic therapies.
• •6. Received anti-cancer therapies within the following time frames prior to the first dose of study treatment:
• •* Conventional cytotoxic chemotherapy: ≤4 weeks
• •* Biologic therapy (eg, antibodies), other than ADCs: ≤4 weeks
• •* Non-cytotoxic small molecule therapeutics: ≤5 T1/2 or ≤2 weeks (whichever is longer)
• •* Other investigational agents: ≤4 weeks
• •* Radiation therapy (palliative setting is allowed.): ≤4 weeks
• •* Major surgery: ≤2 weeks
• •7. Patient has out of range laboratory values defined as:
• •* Hematological values:
• •* Absolute neutrophil count (ANC) \<1.5 x 109/L
• •* Hemoglobin (Hgb) \<9 g/dL
• •* Platelets \<100 x 109/L
• •* Hepatic and renal function
• •* Total bilirubin \>1.5 x upper limit of normal (ULN). For patients with Gilbert's syndrome, total bilirubin \>2.5 x ULN.
• •* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 x ULN for patients without tumor involvement of the liver or \>5 x ULN for patients with tumor involvement of the liver.
• •* Serum creatinine \>1.5 x ULN and/or measured creatinine clearance \< 40 ml/min